Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free BSFA Stock Alerts

BSF Enterprise (BSFA) Competitors

BSF Enterprise logo
GBX 1.40 +0.10 (+7.69%)
As of 08/21/2026 11:55 AM Eastern
Compare

BSFA vs. RGT, CEL, IDP, OPTI, and N4P

Should you buy BSF Enterprise stock or one of its competitors? BSF Enterprise's main competitors and comparable companies include Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), InnovaDerma (IDP), OptiBiotix Health (OPTI), and N4 Pharma (N4P). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BSF Enterprise compare to Argent BioPharma?

Argent BioPharma (LON:RGT) and BSF Enterprise (LON:BSFA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

1.1% of Argent BioPharma shares are held by institutional investors. 17.8% of Argent BioPharma shares are held by insiders. Comparatively, 11.5% of BSF Enterprise shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled BSF Enterprise'saverage media sentiment score.

Company Overall Sentiment
Argent BioPharma Neutral
BSF Enterprise Neutral

BSF Enterprise has higher revenue and earnings than Argent BioPharma. BSF Enterprise is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharmaN/AN/A-£17.53M-£0.24N/A
BSF Enterprise£51.07K53.12-£2.04M-£1.02N/A

Argent BioPharma has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, BSF Enterprise has a beta of 3.614, indicating that its share price is 261% more volatile than the broader market.

Argent BioPharma has a net margin of -1,967.38% compared to BSF Enterprise's net margin of -2,505.69%. Argent BioPharma's return on equity of 279.26% beat BSF Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
Argent BioPharma-1,967.38% 279.26% -108.57%
BSF Enterprise -2,505.69%-57.16%-20.65%

Summary

Argent BioPharma beats BSF Enterprise on 6 of the 10 factors compared between the two stocks.

How does BSF Enterprise compare to Celadon Pharmaceuticals?

Celadon Pharmaceuticals (LON:CEL) and BSF Enterprise (LON:BSFA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled BSF Enterprise'saverage media sentiment score.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
BSF Enterprise Neutral

BSF Enterprise has lower revenue, but higher earnings than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than BSF Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A
BSF Enterprise£51.07K53.12-£2.04M-£1.02N/A

Celadon Pharmaceuticals has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, BSF Enterprise has a beta of 3.614, suggesting that its share price is 261% more volatile than the broader market.

BSF Enterprise has a net margin of -2,505.69% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. BSF Enterprise's return on equity of -57.16% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon Pharmaceuticals-9,520.00% -131.82% -34.40%
BSF Enterprise -2,505.69%-57.16%-20.65%

10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by insiders. Comparatively, 11.5% of BSF Enterprise shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

BSF Enterprise beats Celadon Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does BSF Enterprise compare to InnovaDerma?

BSF Enterprise (LON:BSFA) and InnovaDerma (LON:IDP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

InnovaDerma has higher revenue and earnings than BSF Enterprise. BSF Enterprise is trading at a lower price-to-earnings ratio than InnovaDerma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BSF Enterprise£51.07K53.12-£2.04M-£1.02N/A
InnovaDerma£9.82M0.00N/A-£7.50N/A

InnovaDerma has a net margin of 0.00% compared to BSF Enterprise's net margin of -2,505.69%. InnovaDerma's return on equity of 0.00% beat BSF Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
BSF Enterprise-2,505.69% -57.16% -20.65%
InnovaDerma N/A N/A N/A

In the previous week, BSF Enterprise's average media sentiment score of 0.00 equaled InnovaDerma'saverage media sentiment score.

Company Overall Sentiment
BSF Enterprise Neutral
InnovaDerma Neutral

Summary

InnovaDerma beats BSF Enterprise on 4 of the 6 factors compared between the two stocks.

How does BSF Enterprise compare to OptiBiotix Health?

OptiBiotix Health (LON:OPTI) and BSF Enterprise (LON:BSFA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

0.4% of OptiBiotix Health shares are held by institutional investors. 26.8% of OptiBiotix Health shares are held by company insiders. Comparatively, 11.5% of BSF Enterprise shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

OptiBiotix Health has a beta of 1.824, suggesting that its share price is 82% more volatile than the broader market. Comparatively, BSF Enterprise has a beta of 3.614, suggesting that its share price is 261% more volatile than the broader market.

In the previous week, OptiBiotix Health had 1 more articles in the media than BSF Enterprise. MarketBeat recorded 1 mentions for OptiBiotix Health and 0 mentions for BSF Enterprise. OptiBiotix Health's average media sentiment score of 0.75 beat BSF Enterprise's score of 0.00 indicating that OptiBiotix Health is being referred to more favorably in the media.

Company Overall Sentiment
OptiBiotix Health Positive
BSF Enterprise Neutral

BSF Enterprise has lower revenue, but higher earnings than OptiBiotix Health. OptiBiotix Health is trading at a lower price-to-earnings ratio than BSF Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiBiotix Health£1.17M4.99-£3.09M-£3.84N/A
BSF Enterprise£51.07K53.12-£2.04M-£1.02N/A

OptiBiotix Health has a net margin of -333.62% compared to BSF Enterprise's net margin of -2,505.69%. OptiBiotix Health's return on equity of -52.92% beat BSF Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
OptiBiotix Health-333.62% -52.92% -13.93%
BSF Enterprise -2,505.69%-57.16%-20.65%

Summary

OptiBiotix Health beats BSF Enterprise on 8 of the 13 factors compared between the two stocks.

How does BSF Enterprise compare to N4 Pharma?

N4 Pharma (LON:N4P) and BSF Enterprise (LON:BSFA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

N4 Pharma has higher earnings, but lower revenue than BSF Enterprise. N4 Pharma is trading at a lower price-to-earnings ratio than BSF Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£7.07K800.95-£1.63M-£0.24N/A
BSF Enterprise£51.07K53.12-£2.04M-£1.02N/A

BSF Enterprise has a net margin of -2,505.69% compared to N4 Pharma's net margin of -14,542.71%. BSF Enterprise's return on equity of -57.16% beat N4 Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
N4 Pharma-14,542.71% -119.30% -56.00%
BSF Enterprise -2,505.69%-57.16%-20.65%

0.2% of N4 Pharma shares are held by institutional investors. 22.0% of N4 Pharma shares are held by company insiders. Comparatively, 11.5% of BSF Enterprise shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled BSF Enterprise'saverage media sentiment score.

Company Overall Sentiment
N4 Pharma Neutral
BSF Enterprise Neutral

N4 Pharma has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market. Comparatively, BSF Enterprise has a beta of 3.614, meaning that its share price is 261% more volatile than the broader market.

Summary

BSF Enterprise beats N4 Pharma on 6 of the 11 factors compared between the two stocks.

Get BSF Enterprise News Delivered to You Automatically

Sign up to receive the latest news and ratings for BSFA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BSFA vs. The Competition

Export
MetricBSF EnterprisePharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£2.62M£12.57B£7.37B£2.54B
Dividend YieldN/A2.61%2.53%6.17%
P/E Ratio-1.37789.80272.60367.57
Price / Sales53.12762.12623.8383,481.74
Price / Cash10.3096.7778.6227.89
Price / Book0.4511.8913.057.19
Net Income-£2.04M£2.81B£3.47B£5.89B
7 Day Performance21.63%1.77%2.09%0.30%
1 Month Performance97.18%3.85%6.64%3.31%
1 Year Performance-43.96%6.56%25.02%22.13%

BSF Enterprise Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BSFA
BSF Enterprise
N/AGBX 1.40
+7.7%		N/A-44.0%£2.62M£51.07KN/A12
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/AN/AN/A
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat		N/AN/A£8.22M£123.38KN/A2,780
IDP
InnovaDerma
N/AN/AN/AN/A£8.14M£9.82MN/A8,720
OPTI
OptiBiotix Health
N/AGBX 5.85
+1.7%		N/A-52.6%£6.04M£1.17MN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BSFA) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel